For what concerns immune checkpoint receptors expressed on TAMs and compensatory resistance mechanisms to ICIs, VISTA was found to be elevated in melanoma patients treated with ipilimumab, and a high proportion of VISTA+ TAMs showed the immunosuppressive M2 phenotype [58]. This evidence concerns the gene VSIR and melanoma.